GNI Group Ltd. (3G6.F)

14.50 +0.20 (+1.40%) At close: 08:05AM CEST

GNI Group Ltd.

Nihonbashi-Honcho YS Building
3rd Floor 2-2-2 Nihonbashi-Honcho Chuo-ku
Tokyo 103-0023
Japan
81 3 6214 3600
https://www.gnipharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 843

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Ying Luo Ph.D.	CEO, President, Representative Executive Officer & Chair	211.11k	N/A	1965
Dr. Kosuke Tashiro	Co-Founder	N/A	N/A	N/A
Dr. Cristin Print	Co-Founder	N/A	N/A	N/A
Dr. Stephen Charnock-Jones	Co-Founder	N/A	N/A	N/A
Toshiya Kitagawa	Executive Officer & CFO	N/A	N/A	N/A
Prof. Kan-ichiro Suzuki Ph.D.	VP, Executive Officer & Director	N/A	N/A	1954
Kazuhiro Kawauchi	Executive Officer & Chief Business Development Officer	N/A	N/A	1962

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

Corporate Governance

GNI Group Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.